| Grant number: | 21/05810-7 |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |
| Effective date (Start): | August 01, 2021 |
| Effective date (End): | January 31, 2023 |
| Field of knowledge: | Health Sciences - Medicine |
| Principal Investigator: | Fernando Augusto de Lima Marson |
| Grantee: | Matheus Negri Boschiero |
| Host Institution: | Universidade São Francisco (USF). Campus Bragança Paulista. Bragança Paulista , SP, Brazil |
Abstract Introduction: Few studies have described that COVID-19 in patients with Down Syndrome (DS) is associated with longer intubation time and higher mortality rates, however, most of these studies have their conclusions based on a small sample size. In this context, due to the low sample size, the real impact of the COVID-19 has on DS patients still needs to be better clarified. Therefore, the primary objective of the present study is to evaluate, in a cohort in Brazil, the relative risk for death of patients with DS and COVID-19 when compared with individuals with Severe Acute Respiratory Syndrome (SARS) due to COVID-19 or other etiologic factors. Methods: In the study will be performed an epidemiological analysis of markers available in OpenDataSUS of patients who were diagnosed with SARS in the period between March 2020 and March 2021, that is, one year of the COVID-19 pandemic. Study participants will be divided into 4 groups such as: (G1) participants diagnosed with DS and who were positive for COVID-19; (G2) participants diagnosed with DS and who were not positive for COVID-19 (SARS due to etiological factors other than SARS-CoV-2 infection); (G3) participants with COVID-19 and without DS and/or other comorbidities; (G4) participants diagnosed with SARS due to etiological factors other than SARS-CoV-2 infection and who have not been diagnosed with DS and/or other comorbidities. In the study, the primary outcome will be the analysis of mortality between the different groups described above and the secondary will be: (i) to analysis of mortality according to the need for invasive mechanical ventilation (IMV), hospitalization and admission to the intensive care unit (ICU) for the different groups evaluated; (ii) to analysis of the profile of clinical symptoms between G1 and G2 groups - to describe how COVID-19 can differentiate the clinical presentation from SARS by other factors in DS; (iii) to analysis of the profile of clinical symptoms between groups G1 and G3 - to describe how DS patients are responsive in symptomatology compared to other patients with COVID-19; and finally, (iv) to compare the prevalence of symptoms and comorbidities among individuals in G1 according to the outcome (death and clinical recovery) in order to denote the presence of clinical markers (symptoms and morbidities) with the risk of death due to COVID-19. Expected Results: It is expected that: (i) patients in G1 have worse outcomes (mortality, hospitalization, need for IMV and admission to the ICU) than the other groups; (ii) it is possible to clinically differentiate G1 from G2, and that G1 had symptoms related to worse severity; (iii) it is possible to clinically differentiate G1 from G3 and that G1 had symptoms related to worse severity; (iv) it is possible to predict mortality due to COVID-19 of patients in G1 based on clinical symptoms and comorbidities. (AU) | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| TITULO | |
| Articles published in other media outlets (0 total): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |